Top Stock-Specific News

: Constant currency revenue grew 4.3% QoQ, with management guiding for strong double-digit organic revenue growth in FY27. : Board to consider fundraising via QIP and other avenues at its meeting on July 22. : Secured two orders worth ₹250–600 crore from BWSSB, strengthening its order book. : Received US FDA tentative approval for Olaparib tablets, expanding its oncology product pipeline. : Q1 sales remained flat, while collections increased 30% YoY, indicating healthy cash flow. : Reported its first-ever quarterly profit (PAT positive) in Q1 FY27.